Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression

Cancer Gene Therapy

Volumn 15, Issue 6, 2008, Pages 382-392

  Li, S ^a,b   Yang, J ^a,c   Urban, F A ^a   MacGregor, J N ^a   Hughes, D P M ^a   Chang, A E ^a   McDonagh, K T ^a,d   Li, Q ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Adoptive immunotherapy; Breast cancer; Chimeric receptor; Fibrosarcoma; HER2; IL 2

Indexed keywords

CHIMERIC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY N29; RETROVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FIBROSARCOMA; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LUNG METASTASIS; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; CELL LINE, TUMOR; FIBROSARCOMA; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

MURINAE;

EID: 43749094329     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.5     Document Type: Article

References (45)

1. Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487-1489.
2. Yannelli JR, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer 1996; 65: 413-421.
3. Li Q, Grover A, Donald EJ, Carr A, Yu J, Whitfield J et al. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments theantitumor reactivity of tumor-primed lymph node cells. J Immunol 2005; 175: 1424-1432.
4. MacGregor JN, Li Q, Chang AE, Hughes DPM, McDonagh KT. Ex vivo culture with IL-12 improves CD8+ T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFNg but requires perforin. Cancer Res 2006; 66: 4913-4921.
5. Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG. Phase II trial of autologous tumor vaccination, Anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 2003; 21: 884.
6. Kourilsky P, Jaulin C, Ley V. The structure and function of MHC molecules. Possible implications for the control of tumor growth by MHC-restricted T cells. Semin Cancer Biol 1991; 2: 275-282.
7. Bodmer WF, Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG. Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann NY Acad Sci 1993; 690: 42-49.
8. Restifo N, Marincola F, Kawakami Y, Taubenberger J, Yannelli J, Rosenberg S. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996; 88: 100-108.
9. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-272.
10. + melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Can Res 2005; 65: 1570-1576.
11. Scholten KBJ, Schreurs MWJ, Ruizendaal JJ, Kueter EWM, Kramer D, Veenbergen S et al. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin Immunol 2006; 114: 119-129.
12. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA et al. Experience with the use of high-dose IL-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474.
13. Roychowdhury S, May Jr KF, Tzou KS, Lin T, Bhatt D, Freud AG et al. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Can Res 2004; 64: 8062.
14. + T cells in macaques chronically infected in SIVmac251. J Immunol 2005; 174: 1913.
15. Poggi A, Massaro A, Negrini S, Contini P, Zocchi MR. Tumor-induced apoptosis of human IL-2-activated NK cells: role of natural cytotoxicity receptors. J Immunol 2005; 174: 2653.
16. Brocker T. Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 2000; 96: 1999-2001.
17. Gritzapis A, Mamalaki A, Kretsovali A, Papamatheakis J, Belimezi M, Perez S et al. Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells. Br J Cancer 2003; 88: 1292-1300.
18. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 1993; 151: 6577-6582.
19. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA 1991; 88: 8691-8695.
20. Rosenberg S, Yannelli J, Yang J, Topalian S, Schwartzentruber D, Weber J et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86: 1159-1166.
21. Hwu P, Yang T, Cowherd R, Treisman J, Shafer GE, Eshhar Z et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T cell receptor genes. Can Res 1995; 55: 3369-3373.
22. Dall P, Herrmann I, Durst B, Stoff-Khalili M, Bauerschmitz G, Hanstein B et al. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells. Cancer Immuno Immunother 2005; 54: 51-60.
23. Eshhar Z, Waks T, Schindler DG, Gross G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody binding domains and the g or z subunits of the immunoglobulin and T cell receptors. Proc Natl Acad Sci USA 1993; 90: 720-724.
24. Hwu P, Shafer G, Treisman J. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor g chain. J Exp Med 1993; 178: 361-366.
25. Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Can Res 2003; 63: 2470-2476.
26. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 2005; 65: 9080-9088.
27. Kershaw MH, Jackson JT, Haynes NM, Teng MWL, Moeller M, Hayakawa Y et al. Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol 2004; 173: 2143-2150.
28. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol 1999; 26: 51-59.
29. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93: 552-556.
30. Pusztai L, Esteva F. Continued use of trastuzumab (herceptin)after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest 2006; 24: 187-191.
31. Iizuka K, Nakajima C, Iizuka YM, Takase M, Kato T, Noda S et al. Protection from lethal infection by adoptive transfer of CD8 T cells genetically engineered to express virus-specific innate immune receptor. J Immunol 2007; 179: 1122-1128.
32. Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 2007; 67: 5957-5964.
33. Singh H, Serrano LM, Pfeiffer T, Olivares S, McNamara G, Smith DD et al. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. Cancer Res 2007; 67: 2872-2880.
34. Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L et al. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res 2007; 67: 2425-2429.
35. Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM et al. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern. Can Res 2005; 65: 1063.
36. Hughes DP, Baskar D, Urban FF, Friedman MS, Braun TM, McDonagh KT. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo. Cytotherapy 2005; 7: 396-407.
37. + cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies. J Immunother 2002; 25: 304.
38. + effector T cells mediate indirect interleukin-12-and interferon-γ-dependent suppression of autologous HLA-negative lung tumor xenografts in sever combined immunodeficient mice. Cancer Res 2002; 62: 2611-2617.
39. + T cell-dependent tumor rejection in the anterior chamber of the eye. J Immunol 2003; 171: 2789-2796.
40. Cardin R, Brooks J, Sarawar S, Doherty P. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med 1996; 184: 863-871.
41. Stohlman SA, Bergmann CC, Lin MT, Cua DJ, Hinton DR. CTL effector function within the central nervous system requires CD4+ T cells. J Immunol 1998; 160: 2896-2904.
42. + T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen-and-fas independent fashion. J Immunol 2001; 167: 1090-1096.
43. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174: 2591-2601.
44. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
45. Zhang T, Barber A, Sentman CL. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Can Res 2006; 66: 5927-5933.